IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRADEMARK OFFICE

Atty. Docket No: 55880 (71745)

In re patent application of

COHEN, STEPHEN et al.

Serial No. 09/830,980

Filed: May 2, 2001

For: REGULATOR OF NOTCH SIGNALING ACTIVITY

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- the submission, filed herewith in accordance with 37
 C.F.R. § 1.821(g), does not include new matter;
- 2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
- 3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

James A. Coburn

HARBOR CONSULTING

Intellectual Property Services 1500A Lafayette Road Suite 262 Portsmouth, N.H. 800-318-3021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plication of:

Stephen Cohen, et al.

09/830,980

Filed:

May 2, 2001

For:

X

20231.

Date: September 13, 2001

REGULATOR OF NOTCH SIGNALING ACTIVITY

Box Sequence Assistant Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1. [X] This replies to the Office Letter DATED June 13, 2001.

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the $serial\ number\ from\ the\ return\ post\ card\ or\ the\ attorney's\ docket\ number\ added.$

[X] A copy of the Office Letter is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8a)

2.	Ι, _	Cara Z. Lowen	 	 	

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

envelope addressed to the Assistant Commissioner for Patents, Washington, D.C.

deposited with the United States Postal Service

with sufficient postage as first class mail in an

transmitted by facsimile to the Patent and

FACSIMILE

Trademark Office.

Signature

Donna M. Tomaso

(type or print name of person certifying)

(Submission-Nucleotide and/or Amino Acid Sequence-page 1 of 6)

state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are

(check each item as applicable)

- A. [X] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823.
- B. [X] An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. § 1.821(d).
- C. [X] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.
- D. [] Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:	
Serial No.:	Group No.:
Filed:	Examiner:
For:	

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form "Sequence Identifier" (other application) (this application)

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. 1.821(e).

E. [X] A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

(Submission-Nucleotide and/or Amino Acid Sequence—page 2 of 6)

- [] Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. § 1.821(b).
- F. [] Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.
 - [X] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g).

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

- A. [X] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [X] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5.	Appl	icant is
	[]	a small entity. A statement [] is attached.
	[X]	[] was already filed. other than a small entity.

EXTENSION OF TERM

6.

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

(Submission-Nucleotide and/or Amino Acid Sequence-page 3 of 6)

NOTE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.
7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

(complete (a) or (b) as applicable)

(a) [] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R.
1.17(a)(1)-(4)) for the total number of months checked below:

	Extension (months)	Fee for other than small entity	Fee for small entity
[]	one month two months	\$110.00 \$390.00	\$ 55.00 \$ 195.00
[]	three months four months	\$890.00 \$1,390.00	\$ 445.00\$ 695.00

Fee \$

If an additional extension of time is required, please consider this a petition therefor.

Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below:

(check and complete the next item, if applicable)

[X] An extension for <u>one</u> months has already been secured, and the fee paid therefor of \$110.00is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$ 0.00

OR

(b) [] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

(Submission-Nucleotide and/or Amino Acid Sequence-page 4 of 6)

A duplicate of this transmittal is	
F	EE DEFICIENCY
additional time consumed in making up the deficiency is noted and corrected, the appli included, processing delays are encountere	authorization to charge an account, additional fees are necessary to cover the original deficiency. If the maximum, six-month period has expired before the ication is held abandoned. In those instances where authorization to charge is ed in returning the papers to the PTO finance Branch in order to apply thes rization to charge the deposit account for any fee deficiency should be checked 11-33.
10. [X] If any additional extension and/o	r fee is required, charge Account No. <u>04-1105</u> .
	SIGNATURE(s)
September 13, 2001 Date Dike, Bronstein, Roberts & Cushman Intellectual Property Practice Group EDWARDS & ANGELL, LLP P.O. Box 9169 Boston, MA 02209	Cara Z. Lowen (type or print name of person signing statement) Signature
P.O. Address of Signatory	
(If applicable)	[] Inventor[] Assignee of complete interest[] Person authorized to sign on behalf of assignee
Tel. No.: (617) 439-4444 Reg. No. 38,227	 [X] Practitioner of record [] Filed under Rule 34(a) [] Registration No. [] Other

(Submission-Nucleotide and/or Amino Acid Sequence—page 5 of 6)

(complete the following, if applicable)

SIGNATURE OF PRACTITIONER
(type or print name of practitioner)
P.O. Address